(NASDAQ: PRLD) Prelude Therapeutics's forecast annual revenue growth rate of 156.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.43%.
Prelude Therapeutics's revenue in 2026 is $6,500,000.On average, 5 Wall Street analysts forecast PRLD's revenue for 2026 to be $3,206,128,770, with the lowest PRLD revenue forecast at $0, and the highest PRLD revenue forecast at $6,600,853,350. On average, 3 Wall Street analysts forecast PRLD's revenue for 2027 to be $6,412,257,540, with the lowest PRLD revenue forecast at $6,160,796,460, and the highest PRLD revenue forecast at $6,600,853,350.
In 2028, PRLD is forecast to generate $6,412,257,540 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $13,201,706,700.